Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma [EARLY_Phase 1]
This early-phase study tests daratumumab with dose-adjusted EPOCH for plasmablastic lymphoma and diffuse large B-cell lymphoma across stages…
-
CLINICAL_TRIALS trial_result · 2025-06-27Clinical Trial Update: Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
This completed trial update reports on cardiotoxicity and other late effects after radiotherapy combined with immuno-chemotherapy in non-Hod…
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: A Phase 1 Study of ADI-001 in B Cell Malignancies [Phase 1]
The Phase 1 study of ADI-001 in B cell malignancies has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study of JWCAR239 for B-cell non-Hodgkin lymphoma is not yet recruiting, with indications including diffuse large B-cell lymphoma, f…
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating dose-adjusted EPOCH chemotherapy plus Rituximab in previously untreated aggressive non-Hodgkin lymphoma has complet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of selinexor in combination with ibrutinib for relapsed or refractory chronic lymphocytic leukemia and aggressive non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2025-06-09Clinical Trial Update: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL [Phase 1, Phase 2]
Phase 1/2 study of ATG-010 with lenalidomide and rituximab in adults with diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL [Phase 2]
Phase 2 trial evaluating HMPL-760 plus R-GemOx versus placebo plus R-GemOx in relapsed/refractory diffuse large B-cell lymphoma; the study i…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation [Phase 2]
Phase 2 trial comparing three GVHD prophylaxis regimens in nonmyeloablative or reduced-intensity conditioning unrelated donor transplantatio…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1]
Phase 1 trial evaluating zanubrutinib in combination with lenalidomide, with or without rituximab, in relapsed/refractory diffuse large B-ce…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL
This is an AstraZeneca-sponsored Brazilian clinical trial update for Diffuse Large B Cell Lymphoma (BRA-DLBCL) with the study status listed …
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy [Phase 2]
Phase 2 clinical trial update for glofitamab in relapsed or refractory diffuse large B-cell lymphoma after CD19 CAR-T therapy; the study is …
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma [Phase 2]
A Phase 2 study of Firi-cel for relapsed/refractory diffuse large B-cell lymphoma has terminated; sponsor CARGO Therapeutics provided the st…
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 trial evaluated a conditioning regimen incorporating venetoclax, carmustine, etoposide, cytarabine, and melphalan before stem ce…
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study of CNCT19 CAR-T therapy in patients with relapsed or refractory diffuse large B-cell ly…
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 1]
Epizyme's Phase 1 study of EZM0414 (IPN60210) in relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2025-04-25Clinical Trial Update: Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma [Phase 1]
A Phase 1 trial evaluating the combination of Abexinostat and Ibrutinib in diffuse large B-cell lymphoma and mantle cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2025-04-25Clinical Trial Update: Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma [Phase 2]
A Phase 2 trial of Zanubrutinib combined with standard chemotherapy for diffuse large B-cell lymphoma is suspended. The study lists CD79A/B …
-
CLINICAL_TRIALS trial_result · 2025-04-23Clinical Trial Update: 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) [EARLY_Phase 1]
An early-phase (Phase 1) trial evaluating the PET imaging agent 89Zr-DFO-REGN3767 in patients with diffuse large B-cell lymphoma has complet…
-
CLINICAL_TRIALS trial_result · 2025-04-18Clinical Trial Update: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating pembrolizumab in combination with rituximab or obinutuzumab for relapsed or refractory follicular lymphoma or dif…
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance [EARLY_Phase 1]
This update covers an early-phase trial evaluating circulating tumor DNA monitoring and nivolumab maintenance in Diffuse Large B-Cell Lympho…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting [Phase 4]
This Phase 4 trial assesses outpatient administration of Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma, including diffuse lar…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma [Phase 1]
Phase 1 trial evaluating avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy in patients with relapsed or refractory diffuse large …